This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zielen, S.
Right arrow Articles by Hofmann, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zielen, S.
Right arrow Articles by Hofmann, D.

 Previous Article  |  Next Article 

Infection and Immunity, March 2000, p. 1435-1440, Vol. 68, No. 3
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Immunogenicity and Tolerance of a 7-Valent Pneumococcal Conjugate Vaccine in Nonresponders to the 23-Valent Pneumococcal Vaccine

S. Zielen,* I. Bühring, N. Strnad, J. Reichenbach, and D. Hofmann

Zentrum der Kinderheilkunde, Klinikum der Rheinischen Friedrich-Wilhelms-Universität, 53113 Bonn, Germany

Received 26 July 1999/Returned for modification 30 September 1999/Accepted 3 December 1999

There is still a lack of effective vaccination strategies for patients with a deficient antibody response to bacterial polysaccharide antigens. In an open trial, we evaluated the immunogenicity and tolerance of a new 7-valent pneumococcal conjugate vaccine in 22 infection-prone nonresponders to pneumococcal polysaccharide vaccine and 21 controls. In the patient group, nonresponsiveness was confirmed by repeated vaccination with a 23-valent pneumococcal polysaccharide vaccine. The study protocol provided two doses of the pneumococcal conjugate vaccine, given 4 to 6 weeks apart, for both groups. The antibody response was determined before each vaccination and on follow-up by an enzyme-linked immunosorbent assay and compared to the response in a functional opsonophagocytosis assay. Patients showed a significantly lower postvaccination immune response for all serotypes than did controls. The postvaccination response was serotype dependent. A median titer of >1 µg/ml in patients was recorded only for serotypes 4, 9V, 14, and 19F, which are known to be more immunogenic than serotypes 6B, 18C, and 23F. In the patient group, 70% responded to serotype 19F (Pnc 19F), 65% responded to Pnc 14 and 4, 60% responded to Pnc 9V, 55% responded to Pnc 18C, 50% responded to Pnc 23F, and 25% responded to Pnc 6B. In the control group >95% of individuals showed a titer of >1 µg/ml to every serotype. The vaccine was tolerated well, and no major side effects have been reported. The new pneumococcal conjugate vaccine is clearly more immunogenic in previous nonresponders than is the 23-valent pneumococcal vaccine. Immunization with a pneumococcal conjugate vaccine should be considered as a strategy to protect high-risk patients.

* Corresponding author. Mailing address: Zentrum der Kinderheilkunde, Klinikum der Rheinischen Friedrich-Wilhelms-Universität, 53113 Bonn, Germany. Phone: 0049/228-2873214. Fax: 0049/228-2873446. E-mail: zielen{at}mailer.meb.uni-bonn.de.

Infection and Immunity, March 2000, p. 1435-1440, Vol. 68, No. 3
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Salt, P., Banner, C., Oh, S., Yu, L.-m., Lewis, S., Pan, D., Griffiths, D., Ferry, B., Pollard, A. (2007). Social Mixing with Other Children during Infancy Enhances Antibody Response to a Pneumococcal Conjugate Vaccine in Early Childhood. CVI 14: 593-599 [Abstract] [Full Text]  
  • Balmer, P., Cant, A. J, Borrow, R. (2007). Anti-pneumococcal antibody titre measurement: what useful information does it yield?. J. Clin. Pathol. 60: 345-350 [Abstract] [Full Text]  
  • Meisel, R., Kuypers, L., Dirksen, U., Schubert, R., Gruhn, B., Strauss, G., Beutel, K., Groll, A. H., Duffner, U., Blutters-Sawatzki, R., Holter, W., Feuchtinger, T., Gruttner, H.-P., Schroten, H., Zielen, S., Ohmann, C., Laws, H.-J., Dilloo, D., for the Impfung von Kindern nach allogener Stammze, (2007). Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 109: 2322-2326 [Abstract] [Full Text]  
  • Rose, M. A., Schubert, R., Strnad, N., Zielen, S. (2005). Priming of Immunological Memory by Pneumococcal Conjugate Vaccine in Children Unresponsive to 23-Valent Polysaccharide Pneumococcal Vaccine. CVI 12: 1216-1222 [Abstract] [Full Text]  
  • Vendrell, M., de Gracia, J., Rodrigo, M.-J., Cruz, M.-J., Alvarez, A., Garcia, M., Miravitlles, M. (2005). Antibody Production Deficiency With Normal IgG Levels in Bronchiectasis of Unknown Etiology. Chest 127: 197-204 [Abstract] [Full Text]  
  • Ubukata, K., Chiba, N., Hasegawa, K., Kobayashi, R., Iwata, S., Sunakawa, K. (2004). Antibiotic Susceptibility in Relation to Penicillin-Binding Protein Genes and Serotype Distribution of Streptococcus pneumoniae Strains Responsible for Meningitis in Japan, 1999 to 2002. Antimicrob. Agents Chemother. 48: 1488-1494 [Abstract] [Full Text]  
  • O'Brien, K. L., Santosham, M. (2004). Potential Impact of Conjugate Pneumococcal Vaccines on Pediatric Pneumococcal Diseases. Am J Epidemiol 159: 634-644 [Abstract] [Full Text]  
  • Artz, A. S., Ershler, W. B., Longo, D. L. (2003). Pneumococcal Vaccination and Revaccination of Older Adults. Clin. Microbiol. Rev. 16: 308-318 [Abstract] [Full Text]  
  • Pelton, S. I., Klein, J. O. (2002). The Future of Pneumococcal Conjugate Vaccines for Prevention of Pneumococcal Diseases in Infants and Children. Pediatrics 110: 805-814 [Abstract] [Full Text]  
  • Flamaing, J., Verhaegen, J., Peetermans, W. E. (2002). Streptococcus pneumoniae bacteraemia in Belgium: differential characteristics in children and the elderly population and implications for vaccine use. J Antimicrob Chemother 50: 43-50 [Abstract] [Full Text]  
  • Finn, A, Booy, R, Moxon, R, Sharland, M, Heath, P (2002). Should the new pneumococcal vaccine be used in high-risk children?. Arch. Dis. Child. 87: 18-21 [Abstract] [Full Text]  
  • Spoulou, V., Gilks, C. F, Ioannidis, J. P A (2002). Protein conjugate pneumococcal vaccines. BMJ 324: 750-751 [Full Text]  
  • (2001). Index of Suspicion. Pediatr. Rev. 22: 271-276 [Full Text]  
  • Choo, S, Finn, A (2001). Current topic: New pneumococcal vaccines for children. Arch. Dis. Child. 84: 289-294 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»